Serum hepatitis B core‐related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load

Summary Background Patients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core‐related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication. Aim To explore whether a high HBcrAg level is associated with increas...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Alimentary pharmacology & therapeutics Ročník 53; číslo 8; s. 908 - 918
Hlavní autori:	Tseng, Tai‐Chung, Liu, Chun‐Jen, Yang, Wan‐Ting, Hsu, Chen‐Yang, Hong, Chun‐Ming, Su, Tung‐Hung, Tsai, Cheng‐Hsueh, Chen, Chi‐Ling, Yang, Hung‐Chih, Liu, Chen‐Hua, Chen, Hsiu‐Hsi, Chen, Pei‐Jer, Kao, Jia‐Horng
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Wiley Subscription Services, Inc 01.04.2021
Predmet:	Alanine Alanine transaminase Antigens Chronic infection Cirrhosis Deoxyribonucleic acid Disease Progression DNA DNA, Viral Hepatitis B Hepatitis B Core Antigens Hepatitis B e antigen Hepatitis B e Antigens Hepatitis B virus - genetics Hepatitis B, Chronic - complications Humans Interferon Liver cirrhosis Liver diseases Risk assessment Symptom Flare Up Viral Load
ISSN:	0269-2813, 1365-2036, 1365-2036
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Summary Background Patients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core‐related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication. Aim To explore whether a high HBcrAg level is associated with increased risk of cirrhosis, especially in patients with intermediate viral load (HBV DNA 2000‐19 999 IU/mL) due to their moderate risk of disease progression. Methods A total of 1673 treatment‐naïve, non‐cirrhotic patients with negative hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) level <40 U/L at baseline were enrolled. We explored the relationship between baseline levels of HBcrAg and cirrhosis development in all patients, and whether a higher HBcrAg level (<10 vs ≥10 KU/mL) was associated with an increased risk of disease progression in those with intermediate viral load. Results Of the 1673 patients, 104 developed cirrhosis after a mean follow‐up of 15.9 years. Higher HBcrAg levels were associated with increased incidence of cirrhosis, cirrhosis‐related complications, and liver‐related death. In 445 patients with intermediate viral load, the cirrhosis risk stratified by HBcrAg level of 10 KU/mL yielded a hazard ratio of 3.22 (95% CI: 1.61‐6.47). The risk stratification remained significant when exploring other pre‐cirrhosis endpoints, including HBeAg‐negative hepatitis, hepatitis flare, and HBV DNA >20 000 IU/mL after 3 years of follow‐up. Conclusions In HBeAg‐negative patients with normal ALT levels, higher HBcrAg levels are associated with increased risk of cirrhosis. Among those with intermediate viral load, HBcrAg <10 KU/mL defines a low‐risk group for disease progression.
AbstractList	Patients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core-related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication. To explore whether a high HBcrAg level is associated with increased risk of cirrhosis, especially in patients with intermediate viral load (HBV DNA 2000-19 999 IU/mL) due to their moderate risk of disease progression. A total of 1673 treatment-naïve, non-cirrhotic patients with negative hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) level <40 U/L at baseline were enrolled. We explored the relationship between baseline levels of HBcrAg and cirrhosis development in all patients, and whether a higher HBcrAg level (<10 vs ≥10 KU/mL) was associated with an increased risk of disease progression in those with intermediate viral load. Of the 1673 patients, 104 developed cirrhosis after a mean follow-up of 15.9 years. Higher HBcrAg levels were associated with increased incidence of cirrhosis, cirrhosis-related complications, and liver-related death. In 445 patients with intermediate viral load, the cirrhosis risk stratified by HBcrAg level of 10 KU/mL yielded a hazard ratio of 3.22 (95% CI: 1.61-6.47). The risk stratification remained significant when exploring other pre-cirrhosis endpoints, including HBeAg-negative hepatitis, hepatitis flare, and HBV DNA >20 000 IU/mL after 3 years of follow-up. In HBeAg-negative patients with normal ALT levels, higher HBcrAg levels are associated with increased risk of cirrhosis. Among those with intermediate viral load, HBcrAg <10 KU/mL defines a low-risk group for disease progression. Patients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core-related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication.BACKGROUNDPatients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core-related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication.To explore whether a high HBcrAg level is associated with increased risk of cirrhosis, especially in patients with intermediate viral load (HBV DNA 2000-19 999 IU/mL) due to their moderate risk of disease progression.AIMTo explore whether a high HBcrAg level is associated with increased risk of cirrhosis, especially in patients with intermediate viral load (HBV DNA 2000-19 999 IU/mL) due to their moderate risk of disease progression.A total of 1673 treatment-naïve, non-cirrhotic patients with negative hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) level <40 U/L at baseline were enrolled. We explored the relationship between baseline levels of HBcrAg and cirrhosis development in all patients, and whether a higher HBcrAg level (<10 vs ≥10 KU/mL) was associated with an increased risk of disease progression in those with intermediate viral load.METHODSA total of 1673 treatment-naïve, non-cirrhotic patients with negative hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) level <40 U/L at baseline were enrolled. We explored the relationship between baseline levels of HBcrAg and cirrhosis development in all patients, and whether a higher HBcrAg level (<10 vs ≥10 KU/mL) was associated with an increased risk of disease progression in those with intermediate viral load.Of the 1673 patients, 104 developed cirrhosis after a mean follow-up of 15.9 years. Higher HBcrAg levels were associated with increased incidence of cirrhosis, cirrhosis-related complications, and liver-related death. In 445 patients with intermediate viral load, the cirrhosis risk stratified by HBcrAg level of 10 KU/mL yielded a hazard ratio of 3.22 (95% CI: 1.61-6.47). The risk stratification remained significant when exploring other pre-cirrhosis endpoints, including HBeAg-negative hepatitis, hepatitis flare, and HBV DNA >20 000 IU/mL after 3 years of follow-up.RESULTSOf the 1673 patients, 104 developed cirrhosis after a mean follow-up of 15.9 years. Higher HBcrAg levels were associated with increased incidence of cirrhosis, cirrhosis-related complications, and liver-related death. In 445 patients with intermediate viral load, the cirrhosis risk stratified by HBcrAg level of 10 KU/mL yielded a hazard ratio of 3.22 (95% CI: 1.61-6.47). The risk stratification remained significant when exploring other pre-cirrhosis endpoints, including HBeAg-negative hepatitis, hepatitis flare, and HBV DNA >20 000 IU/mL after 3 years of follow-up.In HBeAg-negative patients with normal ALT levels, higher HBcrAg levels are associated with increased risk of cirrhosis. Among those with intermediate viral load, HBcrAg <10 KU/mL defines a low-risk group for disease progression.CONCLUSIONSIn HBeAg-negative patients with normal ALT levels, higher HBcrAg levels are associated with increased risk of cirrhosis. Among those with intermediate viral load, HBcrAg <10 KU/mL defines a low-risk group for disease progression. BackgroundPatients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core‐related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication.AimTo explore whether a high HBcrAg level is associated with increased risk of cirrhosis, especially in patients with intermediate viral load (HBV DNA 2000‐19 999 IU/mL) due to their moderate risk of disease progression.MethodsA total of 1673 treatment‐naïve, non‐cirrhotic patients with negative hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) level <40 U/L at baseline were enrolled. We explored the relationship between baseline levels of HBcrAg and cirrhosis development in all patients, and whether a higher HBcrAg level (<10 vs ≥10 KU/mL) was associated with an increased risk of disease progression in those with intermediate viral load.ResultsOf the 1673 patients, 104 developed cirrhosis after a mean follow‐up of 15.9 years. Higher HBcrAg levels were associated with increased incidence of cirrhosis, cirrhosis‐related complications, and liver‐related death. In 445 patients with intermediate viral load, the cirrhosis risk stratified by HBcrAg level of 10 KU/mL yielded a hazard ratio of 3.22 (95% CI: 1.61‐6.47). The risk stratification remained significant when exploring other pre‐cirrhosis endpoints, including HBeAg‐negative hepatitis, hepatitis flare, and HBV DNA >20 000 IU/mL after 3 years of follow‐up.ConclusionsIn HBeAg‐negative patients with normal ALT levels, higher HBcrAg levels are associated with increased risk of cirrhosis. Among those with intermediate viral load, HBcrAg <10 KU/mL defines a low‐risk group for disease progression. Summary Background Patients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core‐related antigen (HBcrAg) is a new biomarker for intrahepatic templates for HBV replication. Aim To explore whether a high HBcrAg level is associated with increased risk of cirrhosis, especially in patients with intermediate viral load (HBV DNA 2000‐19 999 IU/mL) due to their moderate risk of disease progression. Methods A total of 1673 treatment‐naïve, non‐cirrhotic patients with negative hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) level <40 U/L at baseline were enrolled. We explored the relationship between baseline levels of HBcrAg and cirrhosis development in all patients, and whether a higher HBcrAg level (<10 vs ≥10 KU/mL) was associated with an increased risk of disease progression in those with intermediate viral load. Results Of the 1673 patients, 104 developed cirrhosis after a mean follow‐up of 15.9 years. Higher HBcrAg levels were associated with increased incidence of cirrhosis, cirrhosis‐related complications, and liver‐related death. In 445 patients with intermediate viral load, the cirrhosis risk stratified by HBcrAg level of 10 KU/mL yielded a hazard ratio of 3.22 (95% CI: 1.61‐6.47). The risk stratification remained significant when exploring other pre‐cirrhosis endpoints, including HBeAg‐negative hepatitis, hepatitis flare, and HBV DNA >20 000 IU/mL after 3 years of follow‐up. Conclusions In HBeAg‐negative patients with normal ALT levels, higher HBcrAg levels are associated with increased risk of cirrhosis. Among those with intermediate viral load, HBcrAg <10 KU/mL defines a low‐risk group for disease progression.
Author	Tsai, Cheng‐Hsueh Yang, Hung‐Chih Chen, Hsiu‐Hsi Kao, Jia‐Horng Tseng, Tai‐Chung Chen, Chi‐Ling Su, Tung‐Hung Hsu, Chen‐Yang Liu, Chen‐Hua Chen, Pei‐Jer Yang, Wan‐Ting Liu, Chun‐Jen Hong, Chun‐Ming
Author_xml	– sequence: 1 givenname: Tai‐Chung orcidid: 0000-0003-0420-8311 surname: Tseng fullname: Tseng, Tai‐Chung organization: National Taiwan University Hospital – sequence: 2 givenname: Chun‐Jen orcidid: 0000-0002-6202-0993 surname: Liu fullname: Liu, Chun‐Jen organization: National Taiwan University College of Medicine Taipei – sequence: 3 givenname: Wan‐Ting surname: Yang fullname: Yang, Wan‐Ting organization: National Taiwan University Hospital – sequence: 4 givenname: Chen‐Yang surname: Hsu fullname: Hsu, Chen‐Yang organization: National Taiwan University – sequence: 5 givenname: Chun‐Ming surname: Hong fullname: Hong, Chun‐Ming organization: National Taiwan University Hospital – sequence: 6 givenname: Tung‐Hung surname: Su fullname: Su, Tung‐Hung organization: National Taiwan University Hospital – sequence: 7 givenname: Cheng‐Hsueh surname: Tsai fullname: Tsai, Cheng‐Hsueh organization: National Taiwan University Hospital – sequence: 8 givenname: Chi‐Ling orcidid: 0000-0002-9696-073X surname: Chen fullname: Chen, Chi‐Ling organization: National Taiwan University College of Medicine Taipei – sequence: 9 givenname: Hung‐Chih surname: Yang fullname: Yang, Hung‐Chih organization: National Taiwan University College of Medicine Taipei – sequence: 10 givenname: Chen‐Hua orcidid: 0000-0003-3622-9707 surname: Liu fullname: Liu, Chen‐Hua organization: National Taiwan University Hospital – sequence: 11 givenname: Hsiu‐Hsi surname: Chen fullname: Chen, Hsiu‐Hsi organization: National Taiwan University – sequence: 12 givenname: Pei‐Jer surname: Chen fullname: Chen, Pei‐Jer organization: National Taiwan University College of Medicine Taipei – sequence: 13 givenname: Jia‐Horng orcidid: 0000-0002-2442-7952 surname: Kao fullname: Kao, Jia‐Horng email: kaojh@ntu.edu.tw organization: National Taiwan University College of Medicine Taipei
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33465271$$D View this record in MEDLINE/PubMed
BookMark	eNp90b1OHDEQAGArAoWDUPACyBJNUiz4Z9e7LgnKDxJSkEJqy-cdcyY--7C9ILo8QpRHzJPEcAQpSMGNp_hmPJ7ZRhshBkBoj5JDWs-RXpVDKpgQr9CMctE1jHCxgWaECdmwgfIttJ3zFSFE9IS9Rluct6JjPZ2hX18hTUu8gJUurriM32MTE_z-8TOB1wVGrENxlxCwhxvwOJdUoXWQcXL5O44Wjy6DzoBXKV4myNnFgF3AZpFicOaf0vcRhJLxrSuLigqkJYyuvoNvXNIe-6jHN2jTap9h9_HeQd8-frg4-dycffl0enJ81hjecdH01o5zMTDWswGENFJQzozuOmsGI3lrej6Mgho60r7r5lQOVrcapK3RwKHnO-jtum5t_HqCXNTSZQPe6wBxyoq1vWwZl0JWevCMXsUphdqdYh2RFZEHtf-opnn9llolt9TpTv2ddgXv1sCkmHMC-0QoUfebVHWT6mGT1R49s8aVOr4Y6gacfynj1nm4-39pdXx-sc74AzNOsa0
CitedBy_id	crossref_primary_10_3390_v13060951 crossref_primary_10_1007_s11901_024_00632_z crossref_primary_10_1093_ofid_ofae241 crossref_primary_10_3390_microorganisms9061146 crossref_primary_10_1053_j_gastro_2023_01_005 crossref_primary_10_1016_j_cgh_2022_02_046 crossref_primary_10_1111_apt_16678 crossref_primary_10_3389_fimmu_2024_1352929 crossref_primary_10_1016_j_cam_2022_114692 crossref_primary_10_3748_wjg_v28_i27_3532 crossref_primary_10_1002_mma_10348 crossref_primary_10_1038_s41575_022_00649_z crossref_primary_10_1056_NEJMc2301248 crossref_primary_10_1111_apt_16698 crossref_primary_10_3350_cmh_2024_0120 crossref_primary_10_1111_apt_17105 crossref_primary_10_1002_hep4_1856 crossref_primary_10_1097_CLD_0000000000000155 crossref_primary_10_14309_ajg_0000000000001691 crossref_primary_10_1097_IPC_0000000000001322
Cites_doi	10.1038/ajg.2017.254 10.1136/gutjnl-2020-321627 10.1111/apt.13170 10.1016/j.jfma.2018.08.020 10.14309/ajg.0000000000000400 10.1111/liv.13416 10.1111/apt.14613 10.1136/gutjnl-2014-306977 10.1016/S0140-6736(15)61412-X 10.1007/s005350300025 10.1053/j.gastro.2019.08.028 10.1093/infdis/jit209 10.1053/j.gastro.2011.04.046 10.1007/s12072-015-9675-4 10.1093/infdis/jir687 10.1111/apt.14619 10.1016/j.cgh.2010.03.006 10.1016/j.jhep.2016.03.013 10.1053/j.gastro.2005.11.016 10.1016/j.jhep.2018.11.030 10.1016/j.jhepr.2020.100113 10.1002/hep.24615 10.1111/jgh.13989 10.1002/hep.29800 10.1097/00001648-200009000-00011 10.1016/j.jhep.2011.11.030 10.1097/00001648-200009000-00012 10.1016/j.jhep.2004.06.031 10.1093/aje/kwu125 10.1016/j.jhep.2020.01.012 10.1111/jvh.13191 10.1002/hep.26041 10.1053/j.gastro.2012.02.007 10.1111/liv.13346
ContentType	Journal Article
Copyright	2021 John Wiley & Sons Ltd 2021 John Wiley & Sons Ltd. Copyright © 2021 John Wiley & Sons Ltd
Copyright_xml	– notice: 2021 John Wiley & Sons Ltd – notice: 2021 John Wiley & Sons Ltd. – notice: Copyright © 2021 John Wiley & Sons Ltd
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK 7U9 H94 K9. M7N 7X8
DOI	10.1111/apt.16266
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Neurosciences Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1365-2036
EndPage	918
ExternalDocumentID	33465271 10_1111_apt_16266 APT16266
Genre	article Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: National Health Research Institutes funderid: NHRI‐EX108‐10807BC – fundername: Ministry of Science and Technology, Taiwan funderid: MOST 106‐2314‐B‐002 ‐136 – fundername: National Taiwan University Hospital funderid: 107‐N4041; 108‐N4157; 109‐N4644; 109‐P05
GroupedDBID	--- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAKAS AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AFBPY AFEBI AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHEFC AIACR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DTERQ E3Z EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FZ0 G-S G.N GODZA GX1 H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TR2 TUS UB1 V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR XG1 YOC ZZTAW ~IA ~WT AAYXX CITATION O8X CGR CUY CVF ECM EIF NPM 7T5 7TK 7U9 H94 K9. M7N 7X8
ID	FETCH-LOGICAL-c3536-7ffdb6822728e69c96132ca55fc8c934c738d61c1d1755b198fa4ae9f19883e73
IEDL.DBID	WIN
ISICitedReferencesCount	20
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000609075500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0269-2813 1365-2036
IngestDate	Thu Oct 02 10:11:33 EDT 2025 Tue Oct 07 06:53:00 EDT 2025 Mon Jul 21 05:38:50 EDT 2025 Tue Nov 18 21:26:07 EST 2025 Sat Nov 29 03:39:32 EST 2025 Sun Sep 21 06:27:46 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	8
Language	English
License	2021 John Wiley & Sons Ltd.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c3536-7ffdb6822728e69c96132ca55fc8c934c738d61c1d1755b198fa4ae9f19883e73
Notes	The Handling Editor for this article was Professor Geoffrey Dusheiko, and it was accepted for publication after full peer‐review. Funding information This work was supported by the grants from the National Taiwan University Hospital (107‐N4041, 108‐N4157, 109‐N4644, 109‐P05), the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST 106‐2314‐B‐002 −136) and the National Health Research Institutes (NHRI‐EX108‐10807BC). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0003-3622-9707 0000-0002-6202-0993 0000-0002-2442-7952 0000-0003-0420-8311 0000-0002-9696-073X
PMID	33465271
PQID	2509239069
PQPubID	2045200
PageCount	11
ParticipantIDs	proquest_miscellaneous_2479423969 proquest_journals_2509239069 pubmed_primary_33465271 crossref_primary_10_1111_apt_16266 crossref_citationtrail_10_1111_apt_16266 wiley_primary_10_1111_apt_16266_APT16266
PublicationCentury	2000
PublicationDate	April 2021 2021-04-00 20210401
PublicationDateYYYYMMDD	2021-04-01
PublicationDate_xml	– month: 04 year: 2021 text: April 2021
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: Chichester
PublicationTitle	Alimentary pharmacology & therapeutics
PublicationTitleAlternate	Aliment Pharmacol Ther
PublicationYear	2021
Publisher	Wiley Subscription Services, Inc
Publisher_xml	– name: Wiley Subscription Services, Inc
References	2004; 41 2012; 142 2019; 70 2017; 2017 2013; 208 2015; 386 2006; 130 2016; 10 2003; 38 2018; 67 2017; 112 2012; 57 2012; 205 2012; 55 2018; 47 2020; 2 2018; 117 2017; 37 2013; 57 2020; 72 2015; 64 2015; 41 2000; 11 2019; 26 2016; 65 2014; 180 2019; 157 2019; 114 2020; 69 2011; 141 2018; 33 2010; 8 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_16_1 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L (e_1_2_8_18_1) 2017; 2017 e_1_2_8_30_1
References_xml	– volume: 33 start-page: 918 year: 2018 end-page: 925 article-title: Hepatitis B virus core‐related antigen levels predict progression to liver cirrhosis in hepatitis B carriers publication-title: J Gastroenterol Hepatol – volume: 26 start-page: 1473 year: 2019 end-page: 1480 article-title: Hepatitis B core‐related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma publication-title: J Viral Hepat – volume: 37 start-page: 995 year: 2017 end-page: 1001 article-title: Hepatitis B virus core‐related antigen as a surrogate marker for covalently closed circular DNA publication-title: Liver Int – volume: 47 start-page: 1397 year: 2018 end-page: 1408 article-title: Anti‐viral therapy can be delayed or avoided in a significant proportion of HBeAg‐negative Caucasian patients in the Grey Zone publication-title: Aliment Pharmacol Ther – volume: 10 start-page: 1 year: 2016 end-page: 98 article-title: Asian‐Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update publication-title: Hepatol Int – volume: 70 start-page: 615 year: 2019 end-page: 625 article-title: Serum hepatitis B core‐related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients publication-title: J Hepatol – volume: 64 start-page: 292 year: 2015 end-page: 302 article-title: Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers publication-title: Gut – volume: 114 start-page: 1753 year: 2019 end-page: 1763 article-title: Phase transition is infrequent among North American adults with e‐antigen‐negative chronic hepatitis B and low‐level viremia publication-title: Am J Gastroenterol – volume: 180 start-page: 160 year: 2014 end-page: 171 article-title: Marginal structural Cox models for estimating the association between beta‐interferon exposure and disease progression in a multiple sclerosis cohort publication-title: Am J Epidemiol – volume: 69 start-page: 1907 issue: 11 year: 2020 end-page: 1912 article-title: Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID‐19 crisis publication-title: Gut – volume: 11 start-page: 550 year: 2000 end-page: 560 article-title: Marginal structural models and causal inference in epidemiology publication-title: Epidemiology – volume: 72 start-page: 1105 year: 2020 end-page: 1111 article-title: HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis publication-title: J Hepatol – volume: 157 start-page: 1518 year: 2019 end-page: 1529 article-title: High level of hepatitis B core‐related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load publication-title: Gastroenterology – volume: 2 start-page: 100113 year: 2020 article-title: Care of patients with liver disease during the COVID‐19 pandemic: EASL‐ESCMID position paper publication-title: JHEP Rep – volume: 57 start-page: 196 year: 2012 end-page: 202 article-title: Follow‐up and indications for liver biopsy in HBeAg‐negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review publication-title: J Hepatol – volume: 142 start-page: 1140 year: 2012 end-page: 1149 article-title: High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load publication-title: Gastroenterology – volume: 55 start-page: 68 year: 2012 end-page: 76 article-title: Determinants of spontaneous surface antigen loss in hepatitis B e antigen‐negative patients with a low viral load publication-title: Hepatology – volume: 141 start-page: 517 issue: 2 year: 2011 end-page: 525 article-title: Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters publication-title: Gastroenterology – volume: 2017 start-page: 370 year: 2017 end-page: 398 article-title: EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection publication-title: J Hepatol – volume: 65 start-page: 48 year: 2016 end-page: 56 article-title: HBcrAg predicts hepatocellular carcinoma development: an analysis using time‐dependent receiver operating characteristics publication-title: J Hepatol – volume: 130 start-page: 678 year: 2006 end-page: 686 article-title: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load publication-title: Gastroenterology – volume: 67 start-page: 1560 year: 2018 end-page: 1599 article-title: Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance publication-title: Hepatology – volume: 208 start-page: 584 year: 2013 end-page: 593 article-title: Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen‐negative carriers by combining viral biomarkers publication-title: J Infect Dis – volume: 57 start-page: 441 year: 2013 end-page: 450 article-title: Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads publication-title: Hepatology – volume: 38 start-page: 153 year: 2003 end-page: 157 article-title: Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus‐related cirrhosis publication-title: J Gastroenterol – volume: 112 start-page: 1564 year: 2017 end-page: 1574 article-title: Fibrosis‐4 index helps identify HBV carriers with the lowest risk of hepatocellular carcinoma publication-title: Am J Gastroenterol – volume: 386 start-page: 1546 year: 2015 end-page: 1555 article-title: Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 publication-title: Lancet – volume: 117 start-page: 868 issue: 10 year: 2018 end-page: 870 article-title: Hepatitis B: from control to cure publication-title: J Formosan Med Assoc – volume: 41 start-page: 659 year: 2004 end-page: 666 article-title: Quantification and genotyping of hepatitis B virus in a single reaction by real‐time PCR and melting curve analysis publication-title: J Hepatol – volume: 41 start-page: 949 year: 2015 end-page: 960 article-title: Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection publication-title: Aliment Pharmacol Ther – volume: 11 start-page: 561 year: 2000 end-page: 570 article-title: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV‐positive men publication-title: Epidemiology – volume: 8 start-page: 535 year: 2010 end-page: 540 article-title: Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase publication-title: Clin Gastroenterol Hepatol – volume: 37 start-page: 1622 year: 2017 end-page: 1631 article-title: Long‐term outcome of inactive and active, low viraemic HBeAg‐negative‐hepatitis B virus infection: Benign course towards HBsAg clearance publication-title: Liver Int – volume: 205 start-page: 54 year: 2012 end-page: 63 article-title: Serum hepatitis B virus‐DNA levels correlate with long‐term adverse outcomes in spontaneous hepatitis B e antigen seroconverters publication-title: J Infect Dis – volume: 47 start-page: 1480 year: 2018 end-page: 1489 article-title: Fibrosis‐4 index predicts cirrhosis risk and liver‐related mortality in 2075 patients with chronic HBV infection publication-title: Aliment Pharmacol Ther – ident: e_1_2_8_21_1 doi: 10.1038/ajg.2017.254 – ident: e_1_2_8_34_1 doi: 10.1136/gutjnl-2020-321627 – ident: e_1_2_8_24_1 doi: 10.1111/apt.13170 – ident: e_1_2_8_3_1 doi: 10.1016/j.jfma.2018.08.020 – volume: 2017 start-page: 370 year: 2017 ident: e_1_2_8_18_1 article-title: EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection publication-title: J Hepatol – ident: e_1_2_8_11_1 doi: 10.14309/ajg.0000000000000400 – ident: e_1_2_8_10_1 doi: 10.1111/liv.13416 – ident: e_1_2_8_9_1 doi: 10.1111/apt.14613 – ident: e_1_2_8_6_1 doi: 10.1136/gutjnl-2014-306977 – ident: e_1_2_8_2_1 doi: 10.1016/S0140-6736(15)61412-X – ident: e_1_2_8_25_1 doi: 10.1007/s005350300025 – ident: e_1_2_8_15_1 doi: 10.1053/j.gastro.2019.08.028 – ident: e_1_2_8_23_1 doi: 10.1093/infdis/jit209 – ident: e_1_2_8_27_1 doi: 10.1053/j.gastro.2011.04.046 – ident: e_1_2_8_19_1 doi: 10.1007/s12072-015-9675-4 – ident: e_1_2_8_4_1 doi: 10.1093/infdis/jir687 – ident: e_1_2_8_7_1 doi: 10.1111/apt.14619 – ident: e_1_2_8_8_1 doi: 10.1016/j.cgh.2010.03.006 – ident: e_1_2_8_14_1 doi: 10.1016/j.jhep.2016.03.013 – ident: e_1_2_8_5_1 doi: 10.1053/j.gastro.2005.11.016 – ident: e_1_2_8_13_1 doi: 10.1016/j.jhep.2018.11.030 – ident: e_1_2_8_35_1 doi: 10.1016/j.jhepr.2020.100113 – ident: e_1_2_8_28_1 doi: 10.1002/hep.24615 – ident: e_1_2_8_36_1 doi: 10.1111/jgh.13989 – ident: e_1_2_8_17_1 doi: 10.1002/hep.29800 – ident: e_1_2_8_31_1 doi: 10.1097/00001648-200009000-00011 – ident: e_1_2_8_26_1 doi: 10.1016/j.jhep.2011.11.030 – ident: e_1_2_8_32_1 doi: 10.1097/00001648-200009000-00012 – ident: e_1_2_8_29_1 doi: 10.1016/j.jhep.2004.06.031 – ident: e_1_2_8_33_1 doi: 10.1093/aje/kwu125 – ident: e_1_2_8_22_1 doi: 10.1016/j.jhep.2020.01.012 – ident: e_1_2_8_16_1 doi: 10.1111/jvh.13191 – ident: e_1_2_8_30_1 doi: 10.1002/hep.26041 – ident: e_1_2_8_20_1 doi: 10.1053/j.gastro.2012.02.007 – ident: e_1_2_8_12_1 doi: 10.1111/liv.13346
SSID	ssj0006702
Score	2.4466586
Snippet	Summary Background Patients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core‐related antigen... Patients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core-related antigen (HBcrAg) is a new... BackgroundPatients with chronic hepatitis B virus (HBV) infection are at risk of developing liver disease. Serum hepatitis B core‐related antigen (HBcrAg) is a...
SourceID	proquest pubmed crossref wiley
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	908
SubjectTerms	Alanine Alanine transaminase Antigens Chronic infection Cirrhosis Deoxyribonucleic acid Disease Progression DNA DNA, Viral Hepatitis B Hepatitis B Core Antigens Hepatitis B e antigen Hepatitis B e Antigens Hepatitis B virus - genetics Hepatitis B, Chronic - complications Humans Interferon Liver cirrhosis Liver diseases Risk assessment Symptom Flare Up Viral Load
Title	Serum hepatitis B core‐related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load
URI	https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fapt.16266 https://www.ncbi.nlm.nih.gov/pubmed/33465271 https://www.proquest.com/docview/2509239069 https://www.proquest.com/docview/2479423969
Volume	53
WOSCitedRecordID	wos000609075500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library customDbUrl: eissn: 1365-2036 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006702 issn: 0269-2813 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1365-2036 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006702 issn: 0269-2813 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwEB2VghAXPltYKKsBceASVMdJbItTW1iBBKsKtWJvkePYaqUlW-0HZ34C4if2lzDjZKOuAKkSt0iZxJY9Yz_bz28AXhmVB-_TkGQVLVEyb2xiQxYSEzgBnCMPCHVMNqHGYz2ZmOMteLu-C9PqQ_QbbhwZcbzmALfV4kqQ24vlG0FwnOW2RSY4e8HXj-N-FC5U5BvSEsMkqRayUxViFk__5eZc9AfA3MSrccIZ3fuvqt6Hux3OxIPWMR7Alm8ewu3P3Un6I_hFg8TqG555ZlQvzxd4iCxoefnjZ7zd4mukJmelTpwyrQhbed1A62pkNjrOAnZnOxgpXq28B5436Fq53Y1fd-qtC-RtX2SJinm8srL0yCTjKU5ntt6B09H7k6MPSZefIXEyl0WiQqirghCGSrUvjDMEDVJnc6aFOSOpp6WuC-FETRglr4TRwWbWkxsYraVXche2m1njnwDmIhjCjoJTkGY6-KqyKt2vlbe2ysnNBvB63VOl68TLOYfGtFwvYqiNy9jGA3jZm160ih1_M9pbd3fZBe2iJDRIcNfsF2YAL_rXFG58hmIbP1uRDSvykxHbPG7dpC9FyqzIUyWostEb_l18eXB8Eh-eXt_0GdxJmU8TWUN7sL2cr_xzuOW-U0fOh3BDTfQQbr77Mjr9NIyh8Buu6Q0c
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB3xUdFeChTabqFlqHroJYjESRxLXACBQMCKw6JyixzHFkjbLNqPnvsTqv5EfgkzTjbqCiohcYuUSWzZM_az_fwG4JuSibM2ckFc0BIltkoH2sUuUI4TwBnyAFf6ZBOy282ur9XlHOxN78LU-hDthhtHhh-vOcB5Q_qfKNd3452Q8Hg6D4sxAQ1O3PDjtNuOw6n0jENaZKggykLR6Aoxj6f9dHY2egQxZxGrn3KOl19W2RV420BN3K99YxXmbPUOli6aw_Q1-EvjxOQn3lgmVY9vR3iArGl5__uPv-BiS6RWZ7FO7DOzCGuFXUdLa2RCOg4cNsc76FletcIH3lZoasXdmV83Aq4j5J1fZJWKob-1MrbIPOM-9ge6XIer46Pe4UnQpGgIjEhEGkjnyiIlkCGjzKbKKEIHkdEJM8OMEtTZIivT0IQlwZSkCFXmdKwteYLKMmGleA8L1aCyHwGT0CmCjyFnIY0zZ4tCy2i3lFbrIiFP68D3aVflptEv5zQa_Xy6jqE2zn0bd-Bra3pXi3Y8ZbQ57e-8idtRToCQEK_aTVUHttvXFHF8jKIrO5iQDYvykxHbfKj9pC1FCPLESIZUWe8O_y8-37_s-YdPzzfdgtcnvYvz_Py0e7YBbyKm13gS0SYsjIcT-xlemV_UqcMvPhIeAKAhDrI
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwEB2VLap6gZaPsqWFAXHgEtTESRxLXArtCtSyWqFW6i1yHFtUWrKr_eDMT0D8xP4SZhxvxAqQkHqLlEls2TP2s_38BuCVkpmzNnFRWtESJbVKR9qlLlKOE8AZ8gBX-2QTcjgsrq7UaAPeru7CtPoQ3YYbR4YfrznA7bR2v0W5ni7exITH8zuwmXISmR5snnweXJ53I3EuPeeQlhkqSopYBGUhZvJ0H6_PR3-AzHXM6iedwf3bVXcH7gWwicetd-zChm0ewNancJz-EH7SSLH8il8s06oX13N8h6xqefP9h7_iYmukdme5ThwztwhbjV1Hi2tkSjpOHIYDHvQ8r1bjA68bNK3m7tqvg4TrHHnvF1mnYubvrSwsMtN4jOOJrh_B5eD04v2HKCRpiIzIRB5J5-oqJ5ghk8LmyijCB4nRGXPDjBLU3aKo89jENQGVrIpV4XSqLfmCKgphpXgMvWbS2CeAWewUAciY85CmhbNVpWVyVEurdZWRr_Xh9aqrShMUzDmRxrhcrWSojUvfxn142ZlOW9mOvxkdrPq7DJE7LwkSEuZVR7nqw4vuNcUcH6Toxk6WZMOy_GTENnutn3SlCJHmWSJjqqx3h38XXx6PLvzD_v-bPoet0cmgPP84PHsK2wnzazyL6AB6i9nSHsJd8436dPYshMIvWgMPWw
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+hepatitis+B+core%E2%80%90related+antigen+level+stratifies+risk+of+disease+progression+in+chronic+hepatitis+B+patients+with+intermediate+viral+load&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Tai%E2%80%90Chung+Tseng&rft.au=Chun%E2%80%90Jen+Liu&rft.au=Wan%E2%80%90Ting+Yang&rft.au=Chen%E2%80%90Yang+Hsu&rft.date=2021-04-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0269-2813&rft.eissn=1365-2036&rft.volume=53&rft.issue=8&rft.spage=908&rft.epage=918&rft_id=info:doi/10.1111%2Fapt.16266&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon